Plain-English translation of NCT05031897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to stem cell transplant for people with blood cancers and blood disorders. The study uses a 'haploidentical' donor—a partially matched family member—which gives more patients access to this lifesaving treatment. Researchers are comparing two different preparation methods before the transplant to see which one works better and causes fewer serious side effects.
Many patients with blood cancers don't have a perfectly matched donor available, which limits their treatment options. This trial exists to make stem cell transplant available to more people by using partially matched family members as donors and to find the safest way to prepare patients for this procedure.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy and either radiation or additional chemotherapy over about two weeks to prepare your body for the transplant. You'll receive donor stem cells on day zero, followed by medications to prevent rejection and support engraftment. You'll have frequent blood tests, bone marrow biopsies, and imaging scans throughout the study, and you'll be followed closely for two years to monitor how well the transplant works and manage any side effects.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States